H. Lorenz

发表

Rituximab in routine care of severe active rheumatoid arthritis

Andreas Krause, U. Müller-Ladner, Hanns-Martin Lorenz, 2018, Zeitschrift für Rheumatologie.

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations

B. Bonnotte, L. Arnaud, Z. Amoura, 2020, Lupus Science and Medicine.

lupus erythematosus clinical manifestations of refractory systemic depletes plasma cells and ameliorates The proteasome inhibitior bortezomib and

Andreas Radbruch, A. Kühl, G. Burmester, 2015 .

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

C. Baerwald, H. Sitter, U. Müller-Ladner, 2018, Zeitschrift fur Rheumatologie.

[Ocular involvement in spondyloarthropathies: HLA B27 associated uveitis].

H. Lorenz, R. Max, F. Mackensen, 2010, Zeitschrift fur Rheumatologie.

The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement

W. Lehmacher, C. Seitz, M. Meurer, 2008, Rheumatology.

Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist?

C. Fiehn, H. Lorenz, K. Mueller, 2005, Annals of the rheumatic diseases.

Personalisierte Medizin in der Auswahl konventioneller Immunsuppressiva und „disease modifying anti-rheumatic drugs“

C. Fiehn, G. Keyßer, H. Lorenz, 2013, Zeitschrift für Rheumatologie.

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

C. Baerwald, Matthias Schneider, U. Müller-Ladner, 2013, Rheumatology International.

Still ' s Disease and Sepsis Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset

M. Schiller, P. Heyder, M. Rau, 2010 .

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial

N. Halama, L. Bullinger, M. Addo, 2022, medRxiv.

SAT0491 Clinical features and complications in a large international cohort of antimda5 patients: a challenge for the future

M. Piga, F. Locatelli, M. González-Gay, 2018, Saturday, 16 JUNE 2018.

Experiences with Rituximab for the Treatment of Autoimmune Diseases with Ocular Involvement

H. Lorenz, V. Schwenger, M. Becker, 2014, The Journal of Rheumatology.

Autologous haematopoietic stem cell transplantation for Behçet’s disease with pulmonary involvement: analysis after 5 years of follow up

Hanns-Martin Lorenz, C. Fiehn, M. Hensel, 2005, Annals of the rheumatic diseases.

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Andreas Radbruch, A. Kühl, G. Burmester, 2015, Annals of the rheumatic diseases.

Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis

M. Schiller, P. Heyder, M. Rau, 2010, The Journal of Rheumatology.

S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION

N. Halama, R. Schlenk, F. Herth, 2022, HemaSphere.

Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature.

B. Bonnotte, L. Arnaud, Z. Amoura, 2018, Rheumatology.

OP0318 TREATMENT TAPERING AND WITHDRAWAL IN RHEUMATOID ARTHRITIS WITH STABLE REMISSION - FINAL ANALYSIS OF THE RETRO STUDY

G. Schett, J. Rech, S. Finzel, 2021, Annals of the Rheumatic Diseases.

Validation of a proxy‐reported SARC‐F questionnaire for current and retrospective screening of sarcopenia‐related functional impairments

K. Hauer, A. Benner, J. Bauer, 2021, Journal of cachexia, sarcopenia and muscle.

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Andreas Krause, C. Baerwald, U. Müller-Ladner, 2012, Zeitschrift fur Rheumatologie.

Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status

G. Schett, M. Englbrecht, J. Rech, 2018, The Journal of Rheumatology.

POS1078 COMPARISON OF PATIENTS WITH AXIAL PsA AND PATIENTS WITH axSpA AND CONCOMITANT PSORIASIS

G. Schett, A. Regierer, H. Lorenz, 2022, Annals of the Rheumatic Diseases.

Familial chilblain lupus caused by an activating mutation in STING

C. Fiehn, H. Lorenz, N. König, 2015, Pediatric Rheumatology Online Journal.

Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.

I. Olivieri, F. Salaffi, M. González-Gay, 2018, Clinical and experimental rheumatology.

OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS?

Andreas Krause, U. Müller-Ladner, A. Regierer, 2021, Annals of the Rheumatic Diseases.

Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial

J. Rech, S. Finzel, M. Feuchtenberger, 2023, Journal of clinical medicine.

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.

A. Ho, T. Bochtler, M. Hensel, 2005, Rheumatology.

AB0531 Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the action study

G. Burmester, K. Pavelka, C. Poncet, 2013 .

Musculoskeletal and neuropsychiatric manifestations are the main source of persisting affection and organ damage in a German population of patients with systemic lupus erythematosus

B. Löwe, A. Ho, C. Fiehn, 2006, Scandinavian journal of rheumatology.

Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome

W. Drexler, C. Fiehn, H. Lorenz, 2009, Rheumatology International.

SAT0056 Retro – Study of Reduction of Therapy in Patients with Rheumatoid Arthritis in Ongoing Remission

G. Schett, M. Englbrecht, J. Rech, 2015 .

THU0066 Do Predictors of IV Abatacept Retention Depend on The Line of Rheumatoid Arthritis Treatment: 12-Month Interim Analysis of The Observational, Prospective Action Study

X. Mariette, A. Cantagrel, R. Alten, 2016 .

S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten

H. Sitter, S. Wassenberg, C. Fiehn, 2018, Zeitschrift für Rheumatologie.